TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03242668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVB using PVC
Description: At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA
Description: PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
Study: NCT03575676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 100mg BID
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 100mg BID
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 200mg BID
Description: Oral
Study: NCT02540161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004 - 18 mg/kg
Description: Sym004 was dosed at 18 mg/kg intravenously every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004 - 18 mg/kg
Description: Sym004 was dosed at 18 mg/kg intravenously every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004 - 24 mg/kg
Description: Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004 - 24 mg/kg
Description: Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
Study: NCT01539928

Intervention type: OTHER
Intervention: Dual FDG-PET/CT
Description: Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
Study: NCT04544839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADLC attachment system with PEEK inserts
Description: Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ADLC attachment system with PEEK inserts
Description: Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists.
Study: NCT03575676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM3355 200mg BID
Description: Oral
Study: NCT03801577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hepaxa
Description: High concentrate EPA and DHA
Study: NCT00177645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Description: inhalation of sodium bicarbonate or sodium chloride
Study: NCT03333486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT01050335

Intervention type: BEHAVIORAL
Intervention: Simuvision Simulator
Description: Participants will perform common surgical procedures on the simulator
Study: NCT03575676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID
Description: Oral
Study: NCT04184596

Intervention type: OTHER
Intervention: Discrete Choice Experiment
Description: An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
Study: NCT01119846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263
Description: GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263
Description: GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263
Description: GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263 matching placebo
Description: Matching placebo to active drug GSK1292263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263 matching placebo
Description: Matching placebo to active drug GSK1292263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side.
Study: NCT00946062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orientation and mobility training
Description: orientation and mobility training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orientation and mobility training
Description: orientation and mobility training
Study: NCT06108583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAlimento : a multicomponent parent training behavioral program to treat feeding difficulties in children with Autism Spectrum Disorder
Description: The program focuses on parent training. Additionally, intervention on sensory integration is implemented directly with children. The program is made up of 12 sessions, which are held weekly, combining group (1.5 hour parent training and child sensory desensitization) with individual sessions. Parent training group sessions (1,3,4,5,7,8), are focused on teaching strategies based on the principles of behavior intervention and specific techniques related to eating. Strategies involve functional behavioral assessment, antecedent-based interventions, extinction of disruptive behaviors, positive reinforcement, modeling and visual supports. Additionally, parents were trained in methods of introducing new foods, such as modifying food presentation or textures. Simultaneously, children attend a group session in a separate room to target sensory issues and receive oral-facial stimulation. Individual sessions (2,6,9) are focused on specific characteristics of each child.
Study: NCT00964405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: Inhaled Long acting muscarinic receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03715452

Intervention type: DEVICE
Intervention: DyeVert Plus Contrast Reduction System
Description: The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
Study: NCT03418597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep local anesthesia + Virtual reality
Description: Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep local anesthesia alone
Description: Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
Study: NCT02264938

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant
Description: Oral supplemmentation with antioxidants
Study: NCT02383355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of own regimen
Description: Continuation of own antiretroviral medication during the 10 weeks follow-up
Study: NCT04594109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral counseling
Description: Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
Study: NCT02819440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
Study: NCT02481752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Approach Avoidance Training
Description: The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM Training
Study: NCT00250432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin acetate
Description: Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.
Study: NCT00323206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12p DNA
Description: Plasmid IL-12 will be administered as an intratympanic (IT) injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratumoral Electroporation
Description: The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
Study: NCT02690844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam mixed with Mucolox®
Description: 1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mucolox® alone
Description: 5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: 1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
Study: NCT00781495

Intervention type: DEVICE
Intervention: Sensewear Bodymedia armband
Description: To assess physical activity levels patients will wear Sensewear bodymedia armband
Study: NCT01523600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness group
Description: The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
Study: NCT01850537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treatment of degenerative disc disease using the PROW LIF
Description: TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
Study: NCT03612076

Intervention type: OTHER
Intervention: Global cost of management of PJI
Description: estimation of the global cost to manage PJI with 2-step exchange over 3 years
Study: NCT00307476

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rusch Nasopharyngeal Airway
Description: For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rusch Nasopharyngeal Airway
Description: For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.
Study: NCT04210739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethason Sodium Phosphate
Description: Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
Study: NCT02748629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien Parietex ProGrip Self-Fixating Mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight Polypropylene Mesh (<38g/m2 after absorption)
Description: Serag Wiessner SERAMESH® PA 15x10 cm
Study: NCT00957489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamax appliance

Intervention type: OTHER
Group type: OTHER
Intervention: Twin-block appliance
Study: NCT03352154

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P300 - Auditory long latency potential
Description: Perform the P300 exams.
Study: NCT03854357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscapularis Rehabilitation
Description: Specific subscapularis rehabilitation exercises which are not included in the current, standard rehabilitation protocol assigned to total shoulder arthroplasty patients post-operatively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation
Description: Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively
Study: NCT04621461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 220 MG
Description: 220mg once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 5 days
Study: NCT03203837

Intervention type: OTHER
Intervention: Plasma collection
Description: We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
Study: NCT01580553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocarnitine Injection
Description: Levocarnitine Injection:5ml:1g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levocarnitine placebo
Description: L-Carnitine injection placebo (5ml:1g)